PSMA-based radioligand therapy for metastatic castration-resistant prostate cancer: The bad berka experience since 2013

Journal of Nuclear Medicine

Volumn 57, Issue , 2016, Pages 97S-104S

  Kulkarni, Harshad R ^a   Singh, Aviral ^a   Schuchardt, Christiane ^a   Niepsch, Karin ^a   Sayeg, Manal ^a   Leshch, Yevgeniy ^a   Wester, Hans Juergen ^b   Baum, Richard P ^a  

^a ZENTRALKLINIK BAD BERKA   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

PSMA; Radioligand therapy; Theranostics

Indexed keywords

GALLIUM 68; LUTETIUM 177; PROSTATE SPECIFIC MEMBRANE ANTIGEN; RADIOLIGAND; GLUTAMATE CARBOXYPEPTIDASE II; GLUTAMATE CARBOXYPEPTIDASE II, HUMAN; MEMBRANE ANTIGEN; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CASTRATION RESISTANT PROSTATE CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; ISOTOPE LABELING; METASTASIS; MOLECULAR IMAGING; OVERALL SURVIVAL; PATIENT MONITORING; PATIENT SELECTION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; ANTAGONISTS AND INHIBITORS; CARCINOMA; EVIDENCE BASED MEDICINE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SECONDARY; TREATMENT OUTCOME;

ANTIGENS, SURFACE; CARCINOMA; EVIDENCE-BASED MEDICINE; GLUTAMATE CARBOXYPEPTIDASE II; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RADIOISOTOPES; RADIOPHARMACEUTICALS; TREATMENT OUTCOME;

EID: 84991320867     PISSN: 01615505     EISSN: 2159662X     Source Type: Journal    
DOI: 10.2967/jnumed.115.170167     Document Type: Article

References (32)

1. Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract. 2011; 65: 1180-1192.
2. Basch E, Loblaw DA, Oliver TK, et al. Systemic therapy in men with metastatic castration-resistant prostate cancer: American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline. J Clin Oncol. 2014; 32: 3436-3448.
3. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med. 2011; 364: 1995-2005.
4. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012; 367: 1187-1197.
5. Parker C, Nilsson S, Heinrich D, et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013; 369: 213-223.
6. 68Ga-PSMA ligand PET/CT in 248 patients with biochemical recurrence after radical prostatectomy. J Nucl Med. 2015; 56: 668-674.
7. 177Lu-labeled prostate-specific membrane antigen radioligand therapy of metastatic castration-resistant prostate cancer: safety and efficacy. J Nucl Med. 2016; 57: 1006-1013.
8. 177Lu-PSMA therapy for metastatic castration-resistant prostate cancer. J Nucl Med. 2016; 57: 1002-1003.
9. 177Lu-labeled PSMA I & T: optimization of a PSMA-targeted theranostic concept and first proof-of-concept human studies. J Nucl Med. 2015; 56: 1169-1176.
10. Puranik AD, Kulkarni HR, Baum RP. Companion diagnostics. Cancer J 2015; 21: 213-217.
11. Baum RP, Kulkarni HR. Theranostics: from molecular imaging using Ga-68 labeled tracers and PET/CT to personalized radionuclide therapy-the Bad Berka experience. Theranostics. 2012; 2: 437-447.
12. Kulkarni HR, Baum RP. Patient selection for personalized peptide receptor radionuclide therapy using Ga-68 somatostatin receptor PET/CT. PET Clin. 2014; 9: 83-90.
13. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999; 35: 1773-1782.
14. Kulkarni HR, Baum RP. Theranostics with Ga-68 somatostatin receptor PET/CT: monitoring response to peptide receptor radionuclide therapy. PET Clin. 2014; 9: 91-97.
15. Bander NH, Trabulsi EJ, Kostakoglu L, et al. Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. J Urol. 2003; 170: 1717-1721.
16. 177lutetium labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. J Clin Oncol. 2005; 23: 4591-4601.
17. 111In PSMA minibody (IAb2-M-DOTA): first results [abstract]. Eur J Nucl Med Mol Imaging 2013; 40(suppl 2): 89.
18. 11C-MCG: synthesis, uptake selectivity, and primate PET of a probe for glutamate carboxypeptidase II (NAALA-Dase). Mol Imaging 2002; 1: 96-101.
19. Barrett JA, Coleman RE, Goldsmith SJ, et al. First-in-man evaluation of 2 high-affinity PSMA-avid small molecules for imaging prostate cancer. J Nucl Med. 2013; 54: 380-387.
20. 131I-labeled small molecule (MIP-1095) targeting PSMA for prostate cancer therapy. Eur J Nucl Med Mol Imaging 2014; 41: 1280-1292.
21. 177Lu PSMA-617 therapy, dosimetry and follow-up in patients with metastatic castration-resistant prostate cancer. Nuklearmedizin. 2016; 55: 123-128.
22. 131I metaiodobenzylguanidine in combination with hyperbaric oxygen therapy in the treatment of prognostically high-risk forms of neuroblastoma [in Czech]. Cas Lek Cesk. 2001; 140: 13-17.
23. Kulkarni H, Weineisen M, Mueller D, et al. First clinical results with Lu-177 PSMA-TUM1 for the treatment of castrate-resistant metastatic prostate cancer [abstract]. J Nucl Med. 2014; 55(suppl 1): 10.
24. 177Lu-PSMA-DKFZ-617 of castrateresistant metastatic prostate cancer. Oncotarget. 2016; 7: 12477-12488.
25. Kratochwil C, Giesel FL, Stefanova M, et al. PSMA-targeted radionuclide therapy of metastatic castration-resistant prostate cancer with Lu-177 labeled PSMA-617. J Nucl Med. 2016; 57: 1170-1176.
26. 177Lu-PSMA-617 as a novel therapeutic option in patients with metastatic castration resistant prostate cancer. Clin Nucl Med. 2016; 41: 522-528.
27. 177Lu-octreotate in patients with metastatic gastroenteropancreatic neuroendocrine tumours. Eur J Nucl Med Mol Imaging 2014; 41: 205-210.
28. 225Ac-PSMA-617 for PSMA targeting alpha-radiation therapy of patients with metastatic castration-resistant prostate cancer. J Nucl Med. July 7, 2016 [Epub ahead of print].
29. 68Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
30. Sweeney CJ, Chen Y, Carducci M. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer. N Engl J Med. 2015; 373: 737-746.
31. Wright GL Jr, Grob BM, Haley C, et al. Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology 1996; 48: 326-334.
32. Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33: 1974-1982.